News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (303 of 347). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (11 of 347). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (33 of 347). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 265 of 347 items have one.
Survey participants less likely to recommend life-sustaining care for patients with dementia, despite documented wishes
People were about 19 percentage points less likely to recommend life-sustaining treatment for a seriously ill patient with dementia than for a patient without dementia, even when an advance directive requested life-sustaining care…
Read at Medical Xpress → Archived copy (7 Oct 2026), Internet ArchiveWhy hearing loss deserves earlier attention in dementia prevention
Dr. Brent Tipping, a geriatrician at Wits Donald Gordon Medical Center (WDGMC), says that hearing loss more than doubles the odds of dementia, with visual impairment (both near and far) also elevating the risk.
Managing misfolded proteins to prevent Parkinson's disease
The protein alpha-synuclein is abundant in healthy brains and plays an important role in enabling communication between nerve cells. However, under certain conditions, misfolded alpha-synuclein proteins can accumulate into toxic clumps inside neurons. …
Read at Medical Xpress →Slow down, reminisce if it feels right: Practical tips for talking to people with dementia
No one likes to feel left out of the conversation—including people living with dementia. Sometimes, all it takes is a little extra thought to make sure everyone feels included.
- Music-based therapeutic interventions for people with dementia (Cochrane review update)
- Cognition and anatomy in three variants of primary progressive aphasia
- The inter-relationship between delirium and dementia: the importance of delirium prevention
- An update on semantic dementia: genetics, imaging, and pathology
STAT+: Nobel-winning optogenetics research has led to experimental treatments for blindness and Alzheimer’s
Optogenetics is now the foundational way through which we are able to understand how the brain…
Why it matters: Optogenetics research has led to experimental treatments for blindness and Alzheimer's, serving as a foundational way to understand brain function.
May need a subscription Based on the outlet (STAT), not a check of this article.
Read at STAT News → Archived copy (5 Oct 2026), Internet ArchiveGene editing approach opens potential new route to Alzheimer's treatment
Dr. Kevin Kemp and his research team at the University of Bristol have converted the high-risk Alzheimer's gene APOE4 into the lower-risk APOE3 gene.
Read at Medical Xpress → Archived copy (29 Sep 2026), Internet ArchiveGenetic analysis reveals potential benefit of aspirin for reducing dementia risk
Low-dose aspirin was associated with a 70% lower risk of dementia among older people with a particular genetic profile, a new Monash University analysis has found, raising the possibility of a more personalized approach to dementia prevention.
Read at Medical Xpress →Glucosamine, a popular joint supplement, linked to faster Alzheimer’s progression
A large health-record analysis found that glucosamine use was associated with a 25% higher likelihood of mild cognitive impairment progressing to dementia. …
Read at ScienceDaily → Archived copy (4 Oct 2026), Internet ArchiveAt-home injection version of Alzheimer’s drug now available in US
In the U.S., people with early Alzheimer’s disease will now have the option for at-home treatment with the approved therapy Leqembi (lecanemab) throughout the entire treatment journey. …
Read at Alzheimer's News Today → Archived copy (2 Oct 2026), Internet ArchiveYour sleep may be hiding an early clue to Alzheimer’s
Frequent micro-awakenings during sleep were linked to higher genetic risk for Alzheimer’s in healthy middle-aged adults who had no symptoms. …
Read at ScienceDaily → Archived copy (28 Sep 2026), Internet ArchiveThis common vitamin was linked to 13% better cognitive scores
Older adults with mild cognitive impairment and sleep problems who took at least 5,000 IU of vitamin D daily scored more than 13% higher on a cognitive test than those taking none. …
Read at ScienceDaily → Archived copy (4 Oct 2026), Internet ArchiveA little movement in midlife could pay off for your brain years later
Exercise and healthy blood sugar levels in midlife may help slow cognitive decline decades later. Physical activity appeared especially beneficial for Mexican American adults, suggesting that some brain-protective factors may differ across populations.
Read at ScienceDaily → Archived copy (17 Aug 2026), Internet ArchiveFDA designation may speed new treatment for Alzheimer’s psychosis
The U.S. Food and Drug Administration (FDA) has granted fast track designation to remlifanserin, an experimental treatment that Acadia Pharmaceuticals is developing for hallucinations and delusions associated with Alzheimer’s disease psychosis. …
Read at Alzheimer's News Today →Lab-grown mini brains may predict which Alzheimer’s treatments will work
Miniature brain models grown from patients’ cells revealed striking differences in how Alzheimer’s-related tissue responds to an antidepressant. …
Read at ScienceDaily → Archived copy (1 Oct 2026), Internet Archive10 surprising ways diabetes and dementia are connected
Diabetes and dementia appear to be closely intertwined, with each condition potentially influencing the other. Problems with insulin and glucose can affect the brain’s energy supply, increase inflammation, and damage blood vessels linked to memory loss. …
- evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease
- Protocol for a Randomized Phase II/III Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Extended-Release Metformin in Amnestic Mild Cognitive Impairment: Metformin in Alzheimer Dementia Prevention (MAP)
Copper drug clears toxic Alzheimer’s proteins and restores memory
A copper-based compound restored the brain’s ability to clear toxic Alzheimer’s proteins, dramatically reducing amyloid buildup and improving memory in laboratory experiments. …
Read at ScienceDaily → Archived copy (20 Sep 2026), Internet ArchiveAwareness month event has new name: Do What You Love to End Alzheimer’s
June is Alzheimer’s & Brain Awareness Month, and the Alzheimer’s Association is holding a wide range of events to raise funds to fuel research and promote awareness of Alzheimer’s disease and other forms of dementia. …
Read at Alzheimer's News Today →CBD may slow Alzheimer’s by calming the brain’s immune system
CBD may be doing far more than just easing pain or anxiety — new research suggests it could help fight Alzheimer’s disease by calming the brain’s runaway immune response. …
Read at ScienceDaily → Archived copy (13 Sep 2026), Internet ArchiveAlzheimer’s drugs may not work and could raise brain risks
Drugs designed to clear amyloid beta from the brain—once seen as a promising path to slowing Alzheimer’s—may not actually help patients in any meaningful way, according to a major review of over 20,000 participants. …
Daily Alzheimer’s pill slows brain shrinkage, boosts cognition
The benefits seen in people with early Alzheimer’s disease after a year of treatment with blarcamesine (Anavex 2-73) were sustained over nearly three years, according to new analysis from the treatment’s developer, Anavex Life Sciences. …
Read at Alzheimer's News Today → Archived copy (1 Jul 2026), Internet ArchiveButler-Williams Scholars Program 2026
Learn about the unique opportunities the Butler-Williams Scholars Program provides for junior faculty, researchers who are new to the field of aging, and postdoctoral fellows.
Why it matters: The Butler-Williams Scholars Program offers specialized opportunities for junior faculty, new aging-field researchers, and postdoctoral fellows.
Read at NIH National Institute on Aging → Archived copy (30 Jul 2026), Internet ArchiveJust 5 weeks of brain training may protect against dementia for 20 years
A simple brain-training program that sharpens how quickly older adults process visual information may have a surprisingly powerful long-term payoff. …
Ending dementia stigma could change its trajectory: Cancer's history shows why
At a recent party, another guest, a nurse, asked what I do for a living. I explained that as a health policy researcher, my work focuses on helping health-care systems coordinate care for dementia as effectively as for major conditions like cancer, diabetes or stroke. …
Why it matters: A health policy researcher highlights the need for health-care systems to coordinate dementia care as effectively as major conditions like cancer.
Read at Medical Xpress → Archived copy (22 Jan 2026), Internet ArchivePowerful new brain PET scanner is opening new research pathways
At the Yale Positron Emission Tomography (PET) Center, an ultra-high-performance brain-dedicated scanner called the NeuroEXPLORER (NX) is redefining what is possible in brain PET imaging.
Why it matters: The NeuroEXPLORER, an ultra-high-performance brain-dedicated PET scanner at the Yale PET Center, is redefining what is possible in brain PET imaging.
Read at Medical Xpress → Archived copy (6 Feb 2026), Internet ArchiveHow AI can create a virtual programmable human and revolutionize drug discovery
From idea, to lab, to clinic, to approval—it's a long and expensive process to bring a drug to market. It also rarely succeeds.
Why it matters: AI can create a virtual programmable human and revolutionize drug discovery, which is key because bringing a drug to market is a long, expensive process that rarely succeeds.
Read at Medical Xpress → Archived copy (17 Dec 2025), Internet ArchiveConnect with NIA at AAIC 2025
Join NIA at the Alzheimer's Association International Conference (AAIC) in Toronto from July 27-31.
Read at NIH National Institute on Aging → Archived copy (22 Sep 2025), Internet ArchiveResearch training spotlight: NIA funding enables researcher-mentor to “pay it forward”
Read about how renowned researcher María J. Marquine, Ph.D.'s helps clinicians understand cognitive differences in aging across populations.
Read at NIH National Institute on Aging → Archived copy (31 Jul 2026), Internet ArchiveNIA-funded small business spotlight: Bone Health Technologies shakes up the market to prevent bone density loss
Read how Bone Health Technologies, an NIA-funded small business, shakes up the market to prevent bone density loss.
Why it matters: Bone Health Technologies, an NIA-funded small business, is shaking up the market to prevent bone density loss.
Read at NIH National Institute on Aging → Archived copy (12 Jul 2025), Internet ArchiveNIA Experimental Aging Research Training Course
Apply by July 11, 2025, for the Annual Summer Training Course in Experimental Aging Research on Sep. 8-12, 2025, which will provide exposure to research programs in the experimental biology of aging.
Read at NIH National Institute on Aging → Archived copy (30 Jul 2026), Internet ArchiveFollow new items in a feed reader: Atom feed.